NovoCure Limited (NVCR)
- Previous Close
22.01 - Open
22.77 - Bid 23.86 x 200
- Ask 23.95 x 200
- Day's Range
22.42 - 24.04 - 52 Week Range
10.87 - 75.16 - Volume
1,505,732 - Avg. Volume
1,409,030 - Market Cap (intraday)
2.571B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.92
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
www.novocure.comRecent News: NVCR
Performance Overview: NVCR
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVCR
Valuation Measures
Market Cap
2.37B
Enterprise Value
2.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.47
Price/Book (mrq)
6.59
Enterprise Value/Revenue
3.98
Enterprise Value/EBITDA
-6.92
Financial Highlights
Profitability and Income Statement
Profit Margin
-36.67%
Return on Assets (ttm)
-11.18%
Return on Equity (ttm)
-48.70%
Revenue (ttm)
525.66M
Net Income Avi to Common (ttm)
-192.74M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
870.15M
Total Debt/Equity (mrq)
165.65%
Levered Free Cash Flow (ttm)
-28.4M